Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies

People with Down syndrome experience distinct immune system dysregulation characterized by interferon hyperactivation and inflammation that increases risk of autoimmune and rheumatic diseases. Recent evidence shows that JAK inhibitors and targeted immunotherapies offer promising treatment options for immune-mediated manifestations in this population, with recognition that Down syndrome-associated arthritis differs from typical childhood arthritis.